Sold as Aramine. Every FDA application for this active ingredient: 1 branded and 5 generic.
As of Nov 15, 2026, FDA lists 6 applications for Metaraminol Bitartrate (sold as Aramine), first approved Sep 29, 1954, with 0 new uses approved and 0 published complete response letters.
| Sep 29, 1954 | AramineNDA 9509 · New dosage form | Merck | 15 | Discontinued |
| Apr 17, 1972 | Metaraminol BitartrateANDA 80722 | Fresenius Kabi USA | 0 | Discontinued |
| Sep 22, 1972 | Metaraminol BitartrateANDA 80431 | Abraxis Pharm | 3 | Discontinued |
| Aug 24, 2021 | Metaraminol BitartrateANDA 211304 | Azurity | 1 | Marketed |
| — | Metaraminol BitartrateANDA 83363 | Elkins Sinn | 0 | Discontinued |
| — | Metaraminol BitartrateANDA 86418 | Gd Searle LLC | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Fresenius Kabi USA
Abraxis Pharm